1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Aduro BioTech, Inc. - Product Pipeline Review - 2015

Aduro BioTech, Inc. - Product Pipeline Review - 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 38 pages

Aduro BioTech, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Aduro BioTech, Inc. - Product Pipeline Review - 2015’, provides an overview of the Aduro BioTech, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aduro BioTech, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Aduro BioTech, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Aduro BioTech, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Aduro BioTech, Inc.’s pipeline products

Reasons to buy

- Evaluate Aduro BioTech, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Aduro BioTech, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Aduro BioTech, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Aduro BioTech, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aduro BioTech, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Aduro BioTech, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Aduro BioTech, Inc. - Product Pipeline Review - 2015
Table of Contents
Aduro BioTech, Inc. Snapshot 5
Aduro BioTech, Inc. Overview 5
Key Information 5
Key Facts 5
Aduro BioTech, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Aduro BioTech, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Aduro BioTech, Inc. - Pipeline Products Glance 12
Aduro BioTech, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Aduro BioTech, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Aduro BioTech, Inc. - Drug Profiles 15
Cell Therapy to Target GM-CSFR for Pancreatic Cancer 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
CRS-207 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
ADU-623 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Cell Therapy to Target GM-CSFR for Melanoma 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ADU-214 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
ADUS-100 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
anthrax vaccine 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Small Molecules for Oncology 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
STINGVAX 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Vaccines for Oncology 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Aduro BioTech, Inc. - Pipeline Analysis 28
Aduro BioTech, Inc. - Pipeline Products by Target 28
Aduro BioTech, Inc. - Pipeline Products by Route of Administration 29
Aduro BioTech, Inc. - Pipeline Products by Molecule Type 30
Aduro BioTech, Inc. - Recent Pipeline Updates 31
Aduro BioTech, Inc. - Dormant Projects 35
Aduro BioTech, Inc. - Locations And Subsidiaries 36
Head Office 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
Aduro BioTech, Inc., Key Information 5
Aduro BioTech, Inc., Key Facts 5
Aduro BioTech, Inc. - Pipeline by Indication, 2015 7
Aduro BioTech, Inc. - Pipeline by Stage of Development, 2015 8
Aduro BioTech, Inc. - Monotherapy Products in Pipeline, 2015 9
Aduro BioTech, Inc. - Out-Licensed Products in Pipeline, 2015 10
Aduro BioTech, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
Aduro BioTech, Inc. - Phase II, 2015 12
Aduro BioTech, Inc. - Phase I, 2015 13
Aduro BioTech, Inc. - Preclinical, 2015 14
Aduro BioTech, Inc. - Pipeline by Target, 2015 28
Aduro BioTech, Inc. - Pipeline by Route of Administration, 2015 29
Aduro BioTech, Inc. - Pipeline by Molecule Type, 2015 30
Aduro BioTech, Inc. - Recent Pipeline Updates, 2015 31
Aduro BioTech, Inc. - Dormant Developmental Projects,2015 35

List of Figures
Aduro BioTech, Inc. - Pipeline by Top 10 Indication, 2015 7
Aduro BioTech, Inc. - Pipeline by Stage of Development, 2015 8
Aduro BioTech, Inc. - Monotherapy Products in Pipeline, 2015 9
Aduro BioTech, Inc. - Pipeline by Top 10 Target, 2015 28
Aduro BioTech, Inc. - Pipeline by Top 10 Route of Administration, 2015 29
Aduro BioTech, Inc. - Pipeline by Top 10 Molecule Type, 2015 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.